114 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
), people with classic CAH were treated with once-daily, oral atumelnant and assessed for safety and efficacy. The trial continues to enroll three … discontinued from the trial. All AEs to-date have been mild to moderate and transient. There were no significant changes in safety labs or electrocardiograms
8-K
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
-2 trial, a new analysis of patient reported outcome data from the Phase 3 PATHFNDR-1 trial, and interim long-term efficacy and safety results at 42
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
-Choice Treatment Option for Acromegaly
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive
Topline … Symptom Diary
Long-Term Data from Open-Label ACROBAT Advance Extension Study Demonstrated Durable Safety, IGF-1, and Symptom Control at Up to 42-Months
8-K
EX-99.3
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof as well as atumelnant’s … drug candidates for additional diseases or the potential for any such new drug candidates to show safety or efficacy and the expected plans and timing
8-K
EX-99.1
hx54vgwvpvk2pg36qqeu
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
8-K
EX-99.1
97r1ccfdh6hgkb92ix4
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
S-3ASR
9vmx3lw1 l5s2288ob
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.1
jsccpa7
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
3l6pjnhwnhrf0u18
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.2
q872b
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.2
g7ioyytykg4
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-99.1
7h2qhv 2qm
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
dfcr7p4 2f1ejj
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
j708160tzcrsymr
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
0e3j2ofozn1jgtarvbb
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
c2k8qz
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
iyjmn6klbnp80puh14v
8 Jan 24
Regulation FD Disclosure
8:03am